Progyny (NASDAQ:PGNY) Releases FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.980-2.09 for the period, compared to the consensus estimate of 1.740. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q2 2026 guidance to 0.500-0.53 EPS.

Progyny Trading Up 2.5%

NASDAQ:PGNY opened at $19.16 on Friday. The company has a 50-day moving average price of $17.87 and a 200-day moving average price of $21.69. Progyny has a 12 month low of $16.10 and a 12 month high of $28.75. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 29.48, a P/E/G ratio of 1.08 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, May 7th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.44 by ($0.15). Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. During the same period in the prior year, the business posted $0.17 earnings per share. The company’s revenue for the quarter was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts forecast that Progyny will post 1.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PGNY shares. Zacks Research cut shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Barclays lowered their price target on shares of Progyny from $29.00 to $23.00 and set an “overweight” rating for the company in a research report on Friday, March 20th. KeyCorp lowered their price target on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, Citizens Jmp raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a research report on Tuesday, January 20th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.91.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the sale, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 7,455 shares of company stock worth $129,515. 9.90% of the stock is currently owned by company insiders.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Raised forward earnings guidance: Progyny issued Q2 EPS guidance of $0.50–$0.53 and FY2026 EPS $1.98–$2.09, both above consensus, which supports upside to earnings expectations. Progyny Announces First Quarter 2026 Results
• Positive Sentiment: Revenue slightly beat estimates and company highlighted strong early-season member engagement — the $328.5M top line topped Street estimates and management pointed to robust demand for women’s health services. Progyny’s Q1 CY2026 sales beat estimates, stock soars
• Positive Sentiment: Share repurchases: the company disclosed repurchasing 8.8 million shares since November, which is shareholder-friendly and can support the stock. Progyny Announces First Quarter 2026 Results
• Neutral Sentiment: Conflicting headline EPS takeaways in media: some outlets (e.g., Zacks) emphasize an adjusted-beat, while the company/other services report different EPS figures — check the press release and call materials for GAAP vs. adjusted definitions. Progyny Q1 Earnings and Revenues Beat Estimates (Zacks)
• Neutral Sentiment: Management commentary available — the full earnings call transcript provides color on membership trends and seasonality that investors will parse for sustainability of demand. Q1 2026 Earnings Call Transcript
• Negative Sentiment: GAAP EPS miss and steep y/y revenue decline: one report shows $0.29 EPS vs. a $0.44 consensus (and revenue down ~26% YoY), which raises questions about margin pressure and cycle timing. Progyny Q1 Results (MarketBeat)
• Negative Sentiment: Analyst/media caution on outlook: some commentary warns the bull case could be dented by “flat” revenue guidance or the quality of the rebound — this is keeping sentiment mixed despite the EPS guidance beat. The Bull Case For Progyny Could Change (Yahoo)

Institutional Trading of Progyny

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Invesco Ltd. increased its stake in Progyny by 17.2% during the 4th quarter. Invesco Ltd. now owns 466,769 shares of the company’s stock valued at $11,987,000 after purchasing an additional 68,473 shares in the last quarter. Caitlin John LLC increased its stake in Progyny by 72.3% during the 4th quarter. Caitlin John LLC now owns 12,796 shares of the company’s stock valued at $329,000 after purchasing an additional 5,371 shares in the last quarter. EP Wealth Advisors LLC bought a new stake in Progyny during the 4th quarter valued at about $275,000. XTX Topco Ltd bought a new stake in Progyny during the 4th quarter valued at about $3,058,000. Finally, VARCOV Co. bought a new stake in Progyny during the 4th quarter valued at about $491,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.